Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with... THOUSAND OAKS ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products ...

He expects more visibility on Amgen’s launch plans for Imdelltra (tarlatamab) and growth strategy for key products like Tepezza and Krystexxa. JPMorgan’s Chris Schott also expects trial ...

Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, ...

Amgen AMGN reported third-quarter 2024 adjusted earnings of ... Lumakras/Lumykras recorded sales of $98 million in the quarter, up 88% from the year-ago period. Imdelltra (tarlatamab), approved for ...

Amgen AMGN will report third-quarter 2024 results ... respectively. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded sales of ...

Amgen AMGN reported third-quarter 2024 adjusted ... up 88% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024 ...

Looking ahead, we remain confident that Amgen is well positioned to deliver ... and we have initiated a Phase Ib study evaluating subcutaneous tarlatamab in patients with second line or later ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.